- Home
- ROIV vs EDU Comparison
ROIV vs EDU Comparison
Compare ROIV & EDU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | EDU |
|---|---|---|
| Founded | 2014 | 1993 |
| Country | United Kingdom | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 8.2B |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | ROIV | EDU |
|---|---|---|
| Price | $21.94 | $54.22 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | $21.94 | ★ $57.87 |
| AVG Volume (30 Days) | ★ 6.5M | 934.5K |
| Earning Date | 11-10-2025 | 01-20-2026 |
| Dividend Yield | N/A | ★ 2.22% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.27 |
| Revenue | $20,329,000.00 | ★ $4,987,826,000.00 |
| Revenue This Year | N/A | $10.59 |
| Revenue Next Year | $376.94 | $10.33 |
| P/E Ratio | ★ N/A | $23.30 |
| Revenue Growth | N/A | ★ 7.29 |
| 52 Week Low | $8.73 | $40.66 |
| 52 Week High | $22.45 | $64.38 |
Technical Indicators
Market Signals| Indicator | ROIV | EDU |
|---|---|---|
| Relative Strength Index (RSI) | 68.21 | 52.74 |
| Support Level | $20.14 | $52.74 |
| Resistance Level | $21.48 | $54.04 |
| Average True Range (ATR) | 0.66 | 1.03 |
| MACD | -0.02 | 0.32 |
| Stochastic Oscillator | 87.12 | 77.35 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About EDU New Oriental Education & Technology Group Inc.
New Oriental Education & Technology is a prominent private education provider in China, offering a wide array of educational services. These include overseas test preparation and consulting services, high school academic tutoring, nonacademic tutoring, and intelligent learning systems and devices. Additionally, the company holds a 57% ownership stake in East Buy, a leading player in the livestreaming e-commerce market.